Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Blood Cancer Journal
|
August 3, 2021
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 23, 2025
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis
Despina Fotiou, Foteini Theodorakakou, Eirini Solia, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 15, 2024
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, et al.
Hemasphere
|
August 5, 2022
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
Ioannis Ntanasis-Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
Blood
|
May 12, 2016
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis
Efstathios Kastritis, Ioannis Papassotiriou, Evangelos Terpos, et al.
Leukemia & Lymphoma
|
December 15, 2016
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens
Dimitrios C Ziogas, Efstathios Kastritis, Evangelos Terpos, et al.
American Journal of Hematology
|
July 19, 2025
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution
Meletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, et al.
American Journal of Hematology
|
April 4, 2017
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy
Efstathios Kastritis, Maria Gavriatopoulou, Maria Roussou, et al.
British Journal of Haematology
|
August 24, 2020
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance
Efstathios Kastritis, Foteini Theodorakakou, Maria Roussou, et al.
Blood Advances
|
December 11, 2019
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone
Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Blood Cancer Journal
|
August 3, 2021
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 23, 2025
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis
Despina Fotiou, Foteini Theodorakakou, Eirini Solia, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 15, 2024
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, et al.
Hemasphere
|
August 5, 2022
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
Ioannis Ntanasis-Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
Blood
|
May 12, 2016
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis
Efstathios Kastritis, Ioannis Papassotiriou, Evangelos Terpos, et al.
Leukemia & Lymphoma
|
December 15, 2016
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens
Dimitrios C Ziogas, Efstathios Kastritis, Evangelos Terpos, et al.
American Journal of Hematology
|
July 19, 2025
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution
Meletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, et al.
American Journal of Hematology
|
April 4, 2017
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy
Efstathios Kastritis, Maria Gavriatopoulou, Maria Roussou, et al.
British Journal of Haematology
|
August 24, 2020
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance
Efstathios Kastritis, Foteini Theodorakakou, Maria Roussou, et al.
Blood Advances
|
December 11, 2019
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone
Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, et al.
Page
of 8